Potent in vivo anti-malarial activity and representative snapshot pharmacokinetic evaluation of artemisinin-quinoline hybrids

Malaria Journal

Volumn 12, Issue 1, 2013, Pages

  Lombard, Marli C ^a   N'Da, David D ^a   Tran Van Ba, Christophe ^b   Wein, Sharon ^b   Norman, Jennifer ^c   Wiesner, Lubbe ^c   Vial, Henri ^b  

^a NORTH WEST UNIVERSITY   (South Africa)

^b CNRS   (France)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Artemisinin; Hybrid; In vivo activity; Malaria; Pharmacokinetics; Quinoline

Indexed keywords

AMINOQUINOLINE DERIVATIVE; ANTIMALARIAL AGENT; ARTEMISININ; ARTESUNATE;

ANTIMALARIAL ACTIVITY; ARTICLE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PARASITEMIA; PLASMODIUM FALCIPARUM; PLASMODIUM VINCKEI; PLASMODIUM VINCKEI INFECTION;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANIMALS; ANTIMALARIALS; ARTEMISININS; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; MALARIA; MICE; PARASITIC SENSITIVITY TESTS; PLASMODIUM; QUINOLINES; TREATMENT OUTCOME;

EID: 84874011719     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-12-71     Document Type: Article

References (22)

1. Artemisinin resistance in Plasmodium falciparum malaria. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, N Engl J Med 2009 361 455 467 10.1056/NEJMoa0808859 19641202
2. Artemisinin resistance: current status and scenarios for containment. Dondorp AM, Yeung S, White L, Nguon C, Day NPJ, Socheat D, von Seidlein L, Nat Rev Micro 2010 8 272 280
3. Emergence of artemisinin-resistant malaria on the Western border of Thailand: a longitudinal study. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, Ler Moo C, Al-Saai S, Dondorp AM, Lwin KM, Singhasivanon P, Day NP, White NJ, Anderson TJ, Nosten F, Lancet 2012 379 1960 1966 10.1016/S0140-6736(12)60484-X 22484134
4. Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults. Ashton M, Hai TN, Sy ND, Huong DX, Van Huong N, Niêu NT, Công LD, Drug Metab Dispos 1998 26 25 27 9443848 (Pubitemid 28071320)
5. Rapid identification of phase I and II metabolites of artemisinin antimalarials using LTQ-Orbitrap hybrid mass spectrometer in combination with online hydrogen/deuterium exchange technique. Liu T, Du F, Wan Y, Zhu F, Xing J, J Mass Spec 2011 46 725 733 10.1002/jms.1943
6. Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects. Asimus S, Elsherbiny D, Hai TN, Jansson B, Huong NV, Petzold MG, Simonsson USH, Ashton M, Fundam Clin Pharmacol 2007 21 307 316 10.1111/j.1472-8206.2007.00471.x 17521300 (Pubitemid 46800472)
7. Hybrid molecules with a dual mode of action: dream or reality? Meunier B, Acc Chem Res 2008 41 69 77 10.1021/ar7000843 17665872
8. Design, synthesis and antimalarial activity of trifluoromethylartemisinin-mefloquine dual molecules. Grelepois F, Grellier P, Bonnet-Delpon D, Begue J, Chembiochem 2005 6 648 652 10.1002/cbic.200400347 15723441 (Pubitemid 40873765)
9. Synthesis and antimalarial activity of a new series of trioxaquines. Singh C, Malik H, Puri SK, Bioorg Med Chem 2004 12 1177 1182 10.1016/j.bmc.2003.11.021 14980628 (Pubitemid 38251307)
10. Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes. Benoit-Vical F, Lelievre J, Berry A, Deymier C, Dechy-Cabaret O, Cazelles J, Loup C, Robert A, Magnaval JF, Meunier B, Antimicrob Agents Chemother 2007 51 1463 1472 10.1128/AAC.00967-06 17242150 (Pubitemid 46586830)
11. Selection of a trioxaquine as an antimalarial drug candidate. Cosledan F, Fraisse L, Pellet A, Guillou F, Mordmuller B, Kremsner PG, Moreno A, Mazier D, Maffrand JP, Meunier B, Proc Natl Acad Sci USA 2008 105 17579 17584 10.1073/pnas.0804338105 18987321
12. Synthesis and antimalarial activity of trioxaquine derivatives. Dechy-Cabaret O, Benoit-Vical F, Loup C, Robert A, Gornitzka H, Bonhoure A, Vial H, Magnaval J, Séguéla J, Meunier B, Chem Eur J 2004 10 1625 1636 10.1002/chem.200305576 15054749
13. A novel artemisinin-quinine hybrid with potent antimalarial activity. Walsh JJ, Coughlan D, Heneghan N, Gaynor C, Bell A, Bioorg Med Chem Lett 2007 17 3599 3602 10.1016/j.bmcl.2007.04.054 17482816 (Pubitemid 46898817)
14. Hybrid drugs for malaria. Walsh JJ, Bell A, Curr Pharm Des 2009 15 2970 2985 10.2174/138161209789058183 19754373
15. Synthesis, in vitro antimalarial and cytotoxicity of artemisinin- aminoquinoline hybrids. Lombard MC, N'Da DD, Breytenbach JC, Smith PJ, Lategan CA, Bioorg Med Chem Lett 2011 21 1683 1686 10.1016/j.bmcl.2011.01.103 21316959
16. 2-(10β-dihydroartemisinoxy)ethylbromide. Lombard MC, Fernandes MA, Breytenbach JC, N'Da DD, Acta Crys E 2010 E66 2182 2183
17. Human malaria parasite in continuous culture. Trager W, Jensen JB, Science 1976 193 673 675 10.1126/science.781840 781840
18. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Desjardins RE, Canfield CJ, Haynes JD, Chulay JD, Antimicrob Agents Chemother 1979 16 710 718 10.1128/AAC.16.6.710 394674 (Pubitemid 10082023)
19. Optimisation of flow cytometric measurement of parasitaemia in Plasmodium-infected mice. Barkan D, Ginsburg H, Golenser J, Int J Parasitol 2000 30 649 653 10.1016/S0020-7519(00)00035-7 10779580 (Pubitemid 30209951)
20. Liquid chromatography-tandem mass spectrometry assay for the quantitation of β-dihydroartemisinin in rat plasma. Xing J, Yan H, Wang R, Zhang L, Zhang S, J Chromatogr B 2007 852 202 207 10.1016/j.jchromb.2007.01.017 (Pubitemid 46830105)
21. Pharmacokinetics of dihydroartemisinin in a murine malaria model. Batty KT, Gibbons PL, Davis TME, Ilett KF, Am J Trop Med Hyg 2008 78 641 642 18385362 (Pubitemid 351845170)
22. Pharmacokinetics of artemisinin-type compounds. Navaratnam V, Mansor SM, Sit N, Grace J, Li Q, Olliaro P, Clin Pharmacokinet 2000 39 255 270 10.2165/00003088-200039040-00002 11069212